Drug Profile
TA 5493
Alternative Names: TA-5493Latest Information Update: 09 Aug 2010
Price :
$50
*
At a glance
- Originator Tanabe Seiyaku
- Developer Mitsubishi Tanabe Pharma Corporation
- Class Antipsoriatics; Antirheumatics
- Mechanism of Action P38 mitogen-activated protein kinase inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- Discontinued Psoriasis; Rheumatoid arthritis
Most Recent Events
- 27 May 2010 TA 5493 is still in phase I trials for Rheumatoid arthritis and psoriasis in the EU
- 01 Oct 2007 Tanabe Seiyaku Co. Ltd has merged with Mitsubishi Pharma Corporation to form Mitsubishi Tanabe Pharma Corporation
- 28 Aug 2006 Phase-I clinical trials in Psoriasis in Japan (unspecified route)